Cambridge Investment Research Advisors’s MaxLinear MXL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.43M Buy
+11,152
New +$789K ﹤0.01% 1824
2023
Q3
Sell
-7,498
Closed -$237K 3227
2023
Q2
$237K Sell
7,498
-801
-10% -$23.2K ﹤0.01% 2733
2023
Q1
$292K Buy
8,299
+548
+7% +$19.9K ﹤0.01% 2515
2022
Q4
$263K Sell
7,751
-1,754
-18% -$59.4K ﹤0.01% 2532
2022
Q3
$310K Hold
9,505
﹤0.01% 2337
2022
Q2
$323K Buy
9,505
+4,207
+79% +$176K ﹤0.01% 2316
2022
Q1
$309K Buy
5,298
+955
+22% +$58.1K ﹤0.01% 2527
2021
Q4
$327K Buy
+4,343
New +$278K ﹤0.01% 2450
2020
Q2
Sell
-26,831
Closed -$313K 2495
2020
Q1
$313K Buy
26,831
+6,900
+35% +$116K ﹤0.01% 1656
2019
Q4
$423K Buy
19,931
+1,000
+5% +$20.7K ﹤0.01% 1685
2019
Q3
$424K Buy
+18,931
New +$419K ﹤0.01% 1614
2016
Q4
Sell
-18,034
Closed -$366K 1779
2016
Q3
$366K Buy
+18,034
New +$354K 0.01% 1196

Other funds holding MXL

Cambridge Investment Research Advisors's MXL Position: Q2 2026 in Review

Cambridge Investment Research Advisors opened a new position in MaxLinear (MXL) in Q2 2026: 11,152 shares worth $1.43M. The stake represents ﹤0.01% of the portfolio and ranks #1824 among its holdings. This is a return to the name: Cambridge Investment Research Advisors previously reported a position in MXL as recently as Q2 2023.

Cambridge Investment Research Advisors first reported a position in MXL in Q3 2016 and has held it in 12 quarters since. 95 funds tracked by Wall St. Rank hold MXL as of Q2 2026.

  • Cambridge Investment Research Advisors held 11,152 shares of MaxLinear worth $1.43M as of Q2 2026.
  • MaxLinear was a new Cambridge Investment Research Advisors position in Q2 2026.
  • MaxLinear made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1824 holding.
  • Cambridge Investment Research Advisors first reported a position in MaxLinear in Q3 2016 and has held it in 12 quarters since.
  • 95 funds tracked by Wall St. Rank held MaxLinear as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.